Introduction {#Sec1}
============

Dear Editor,

Up to 20 % of children with severe asthma have no signs of eosinophilic inflammation \[[@CR1]\] and these pediatric patients respond poorly to inhaled corticosteroids and anti-IgE, pharmacotherapy that was originally designed to target severe Th2-mediated inflammation \[[@CR2]\]. For these patients, there is a need to increase the understanding of the immunological events underlying the disease, to establish biomarkers for improved diagnosis and monitoring, as well as to identify potential targets for therapy \[[@CR2]\].

The presumed Th17 cytokine interleukin (IL)-26 is an intriguing member of the IL-10 family; one that is involved in several chronic inflammatory disorders and can exert both pro- and anti-inflammatory actions, depending upon the setting \[[@CR3]\]. However, there is currently no conclusive information on the involvement of IL-26 in the pathogenesis of asthma or any other chronic inflammatory airway disorder \[[@CR4]\]. A recent study on healthy human subjects indicates that this cytokine is produced by Th17 cells, as well as by other leukocytes, and that IL-26 contributes to the mobilization of neutrophils in the airways during activation of pulmonary host defense by endotoxin \[[@CR5]\]. Given these facts, we hypothesized that local IL-26 is associated with severe disease in pediatric asthma lacking signs of eosinophilic inflammation.

Methods {#Sec2}
=======

To address our hypothesis, we utilized data from a previously well-characterized cohort of school-age children (*n* = 76) with severe uncontrolled (uncontrolled) or persistent controlled (controlled) asthma \[[@CR6]\]. Briefly, uncontrolled asthma was diagnosed in a child with reduced asthma control despite treatment with high doses of inhaled corticosteroids (≥800 μg budesonide equivalent *per* 24 h), whereas controlled asthma was defined as children having an acceptable asthma control with a low to moderate daily dose of inhaled corticosteroids (100--400 μg budesonide equivalent *per* 24 h). The patients were recruited as previously described \[[@CR6]\], after approval by the Regional Ethics Review Committee in Stockholm (Stockholm) and after informed consent from each patient or parent, in full accordance with the Helsinki declaration.

We quantified IL-26 protein concentrations in the airways in relation to asthma severity, blood eosinophils (B-EOS), exhaled nitric oxide (FENO) and blood neutrophils (B-NEUTRO). Specifically, we utilized cell-free samples of induced sputum \[[@CR7]\] for the measurement of IL-26 protein concentrations (ng/mL) with ELISA (Cusabio Biotech®) \[[@CR5]\].

Results {#Sec3}
=======

Among our included pediatric patients, the median age (range) was 13.7 years (7--19), with 41 % being females. The 48 patients with uncontrolled asthma had a reduced score on the asthma control test (17 versus 23, *p* \< 0.001), and a lower FEV~1~ (82 % versus 90 % predicted, *p* = 0.04) despite receiving a higher dose of inhaled corticosteroids (800 μg versus 320 μg of budesonide, *p* \< 0.001) compared to the 28 children with controlled asthma. In addition, the children with uncontrolled asthma had higher concentrations of B-EOS (0.4 versus 0.2, *p* = 0.02) and B-NEUTRO (3.2 versus. 2.6, *p* = 0.03) than those with controlled asthma.

In the entire cohort, the median FENO levels were 18.3 p.p.b and the median B-EOS concentration was 0.3×10^9^/L. These median values were used to categorize children into groups with high and low levels of these biomarkers of Th2-mediated inflammation, independently of the predefined severity classification.

Among children with low concentrations B-EOS (≤0.3\*10^9^/L), we observed higher concentrations of IL-26 in uncontrolled compared to controlled asthma (Fig. [1a](#Fig1){ref-type="fig"} & Table [1](#Tab1){ref-type="table"}). Furthermore, we found a corresponding association between asthma control and IL-26 concentrations among children with low levels of FENO (Fig. [1b](#Fig1){ref-type="fig"} & Table [1](#Tab1){ref-type="table"}). A trend towards an association between asthma control and IL-26 concentrations in the entire cohort was observed, but it was not statistically significant (Table [1](#Tab1){ref-type="table"}). Furthermore, when investigating children with high concentrations of B-EOS and high levels of FENO, the difference in distribution of IL-26 between children with uncontrolled and controlled asthma was less pronounced (Table [1](#Tab1){ref-type="table"}).Fig. 1Median concentrations (logarithmically transformed) of IL-26 (ng/mL) in induced sputum from children with uncontrolled versus controlled asthma and **a** low concentrations of eosinophils in blood (≤0.3 × 10^9^/L) or **b** low levels of exhaled nitric oxide (≤ 18.3 p.p.b)Table 1Interleukin-26 in the airways of children with uncontrolled versus controlled asthmaIL-26 (ng/ml) Uncontrolled asthmanIL-26 (ng/ml) Controlled asthman*p*-value\*All patients4.4 (1.9--14)482.4 (1.3--4.5)280.077Low B-EOS (≤ 0.3×10^9^/L)4.6 (2.3--13)272.3 (1.3--4.5)220.038\*High B-EOS (\>0.3×10^9^/L)4.1 (1.7--16)212.9 (1--31)50.61Low FENO (≤18.3 p.p.b.)4.1 (2.2--16)232.0 (1.2--3.6)130.055High FENO (\>18.3 p.p.b)5.0 (1.8--13)252.7 (1.4--24)150.54*Footnotes*. The IL-26 concentrations are presented as medians with inter-quartile rangesThe median values in the entire cohort of the respective biomarker were used to define the cut-off between high and low levels of the various biomarkers. *B-EOS* blood eosinophils, *FENO* the fraction of nitric oxide in exhaled air, in parts per billion. \*Independent samples, analyzed by Mann--Whitney U-test (SPSS® version 20)

Finally, we found a weak but statistically significant correlation (the Pearson test: *r* = 0.27, *p* = 0.018, *n* = 76) between the concentrations of B-NEUTRO and IL-26 in the entire cohort of pediatric patients with asthma and this correlation tended to be stronger in the patients with low levels of FENO (*r* = 0.35, *p* = 0.036, *n* = 36). There was no evident correlation between IL-26 concentrations and age, gender, height or dose of inhaled corticosteroids.

Discussion {#Sec4}
==========

Our study is the first to associate local IL-26 protein concentrations in the airways with a certain clinical phenotype of pediatric asthma. The fact that IL-26 protein concentrations are increased in sputum from pediatric patients with uncontrolled asthma but without signs of Th2-mediated inflammation forwards IL-26 as a potential, novel biomarker of disease severity in this phenotype of asthma. These findings are also supported by a positive correlation between local IL-26 and systemic neutrophils (ie. B-NEUTRO); a correlation in line with a mechanistic link between IL-26 and the mobilization of neutrophils as recently indicated in human airways \[[@CR5], [@CR8]\].

One of the effects of treatment with inhaled corticosteroid is an inhibition of the production of Th2 cytokines such as IL-4 and IL-5, which subsequently attenuate eosinophilic recruitment and the release of toxic granulae proteins \[[@CR9]\]. The observed clinical effects are an improvement of symptoms and pulmonary function and a reduced rate of asthma exacerbations \[[@CR10]\]. It is widely accepted that increased concentrations of blood eosinophils and high levels of FENO indicate systemic and local eosinophilic inflammation, respectively \[[@CR11], [@CR12]\]. In addition, it is known that low levels of these established biomarkers are associated with a reduced sensitivity to inhaled steroids \[[@CR13], [@CR14]\]. Given that our findings are compatible with an increase in local IL-26 being associated with inflammation not mediated by Th2-related mechanisms; this observation forwards the clinically relevant question whether IL-26 is also linked to low sensitivity to inhaled steroids in pediatric patients with non-allergic asthma? New studies are required to address this possibility; a possibility that has implications for the estimated 13 % of children with severe asthma displaying excess neutrophil mobilization \[[@CR1]\].

Even though the size of our study material was modest, a particular strength of our current analysis is the standardized and detailed characterization of each individual patient; making it possible to identify various subgroups within this cohort. We think that this facilitated the discovery that IL-26 provides a potentially clinically relevant signal in patients without signs of local or systemic eosinophilic inflammation.

Conclusion {#Sec5}
==========

Our pilot study demonstrates that local IL-26 bears potential as a biomarker of disease severity in a clinical phenotype of pediatric asthma that is perpetuated by other than Th2-related mechanisms.
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